ArticleEClinicalMedicine2023

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial.

Wei Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.